Will the first-line induction therapy of bortezomib for newly diagnosed multiple myeloma be challenged in the era of novel drugs?
10.3760/cma.j.issn.1009-9921.2017.12.003
- VernacularTitle:新药时代硼替佐米在初治多发性骨髓瘤中的一线诱导治疗地位会受到挑战吗?
- Author:
Lele ZHANG
1
;
Jian LI
Author Information
1. 100730,北京协和医院血液内科
- Keywords:
Multiple myeloma;
Newly diagnosed;
Bortizomib;
Novel agents
- From:
Journal of Leukemia & Lymphoma
2017;26(12):712-715
- CountryChina
- Language:Chinese
-
Abstract:
For newly diagnosed multiple myeloma (MM) patients, bortizomib based on chemotherapy has achieved desirable complete remission rate, good progression-free survival and overall survival, which is now a first-line choice in both transplant-eligible and transplant-ineligible patients. In recent years, other new treatment options such as proteasome inhibitors , immunomodulators , monoclonal antibody and cellular immunotherapy have posed a challenge to the first-line therapeutic status of bortizomib because of their favorable efficacy and safety. Oral proteasome inhibitor or monoclonal antibody combined with immunomodulators and dexamethasone might become the first-line induction therapy of newly-diagnosed MM patients. Moreover, chimeric antigen receptor T-cell immunotherapy (CAR-T) may also play a role in the first-line treatment, especially for the induction therapy of high-risk patients and the consolidation treatment of the elimination in minimal residual disease.
